Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform


Year of Award:
2018
Status:
Complete
Award Type:
R33
Project Number:
CA223908
RFA Number:
RFA-CA-17-011
Technology Track:
Molecular & Cellular Analysis Technologies
PI/Project Leader:
KONRY, TANIA TALI
Other PI or Project Leader:
EVENS, ANDREW M;HUANG, TONY JUN
Institution:
NORTHEASTERN UNIVERSITY

B cell non-Hodgkin lymphomas (bNHL) are the most common lymphoma subtype representing >85% ofall NHLs. bNHL are typically treated the anti-CD20 antibody (e.g., rituximab) alone or in combination withchemotherapy. There are currently, however, no biologica